World Pharmaceutical Frontiers

MSD's doravirine/islatravir combo yields positive results in Phase 3 HIV-1 trials The doravirine/islatravir combination met primary efficacy and safety objectives in two Phase 3 trials involving adults with virologically suppressed HIV-1 Read more: https://lnkd.in/eXVpmm4k #pharmanews #gileadsciences #pharmaceuticalindustry #clinicaltrials #clinicalresearch #hiv #MSD #WorldPharma

Astellas Pharma, Sangamo Therapeutics, Inc. sign licensing agreement for genomic medicines Sangamo will receive a $20m upfront license fee and is eligible to earn up to $1.3bn in additional licensed target fees and milestone payments across all five potential disease targets, along with tiered royalties Read more: https://lnkd.in/eX7jHHzV #pharmanews #pharmaceuticalindustry #drugresearch #genomics #researchanddevelopment #r&d #worldpharma #druglicensing

MSD gets rights to Hansoh Bio Pharma’s investigational diabetes drug MSD gets an exclusive global license to develop, manufacture and commercialise HS-10535, in exchange for an upfront payment of $112m and up to $1.9bn in milestone payments, along with royalties Read more: https://lnkd.in/gxxPgZig #pharmanews #pharmaceuticalindustry #merck #diabetes #drugmanufacturing #hansohpharma #worldpharma #MSD

Accord Healthcare Limited announces that the European Commission (EC) has granted marketing authorisation for Imuldosa (development code: DMB-3115), a biosimilar of Stelara (ustekinumab), marketed by The Janssen Pharmaceutical Companies of Johnson & Johnson Read more: https://lnkd.in/eEwrqmw7 #pharmanews #pharmaceuticalindustry #biosimilars #biopharma #ustekinumab #accordhealthcare #janssenbiotech #worldpharma

GSK secures European Medicines Agency PRIME designation for investigational ADC GSK’227 is an investigational B7-H3-targeted antibody-drug conjugate (ADC) and its PRIME Designation is based on preliminary clinical data from an ongoing open-label, multi-centre Phase 1 study, dubbed ARTEMIS-001 Read more: https://lnkd.in/euEsvwEB #pharmanews #pharmaceuticalindustry #antibodydrugconjugate #clinicaltrials #gsk #EMA #worldpharma

AbbVie to acquire Nimble Therapeutics in $200m deal The deal will provide AbbVie access to Nimble's proprietary peptide synthesis platform, which facilitates the discovery and optimisation of oral peptide therapeutics. Read more: https://lnkd.in/eXbg4W8f #pharmaindustry #pharmaceuticalindustry #peptidesynthesis #peptidethrapeutics #abbvie #nimbletherapeutics #worldpharma

Conduit Pharmaceuticals taps Sarborg for AI and cybernetics in drug development Conduit will retain a non-exclusive, royalty-free, and assignable right to use any platform or technology developed by Sarborg, to evaluate drug repurposing, drug discovery, solid-form identification, and clinical trial monitoring Read more: https://lnkd.in/ee6cwByr #pharmanews #pharmaceuticalindustry #drugdevelopment #artificialintelligence #clinicaltrialmonitoring #worldpharma #conduit #sarborg

Ori Biotech, Fresenius Kabi partner to advance cell and gene therapies Fresenius Kabi will integrate Ori’s IRO platform, developed to address the current challenges in cell and gene therapy (CGT) manufacturing, with its Cue and Lovo Cell Processing Systems Read more: https://lnkd.in/gv6ex7CS #pharmanews #pharmaceuticalindustry #cellandgenetherapy #cgtmanufacturing #biopharmaceuticals #biopharma #drugmanufacturing #cdmo #cgt #cellprocessing #bioprocess #worldpharma #oribiotech #freseniuskabi #advancedtherapy

Arvinas, Pfizer’s vepdegestrant shows promise in ER+/HER2- breast cancer trial The combination showed promising clinical activity, with a 62.5% clinical benefit rate and 26.7% overall response rate in patients previously treated with a CDK4/6 inhibitor Read more: https://lnkd.in/egNY_V8J #pharmanews #oncology #pharmaceuticalindustry #breastcancer #vepdegestrant #worldpharma #pfizer #arvinas

US FDA accepts application for expanded use of Nucala in COPD GSK seeks FDA approval for Nucala as an add-on maintenance treatment for patients with chronic obstructive pulmonary disease (COPD) with an eosinophilic phenotype, based on data from the MATINEE study Read more: https://lnkd.in/efYDtnNx #pharmanews #pharmaceuticalindustry #gsk #fda #worldpharma #copd #respiratorytreatment